|Systematic (IUPAC) name|
|Mol. mass||339.402 g/mol|
Edivoxetine (INN; LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly as an antidepressant and as a treatment for attention-deficit hyperactivity disorder (ADHD). As of 2012, it is in phase III clinical trials for major depressive disorder, with initial approval expected by 2013.
In a study published in 2010, edivoxetine failed to prove superiority over placebo, as measured by Hamilton Depression Rating Scale. However, effectiveness could be observed using the Self-Rated Quick Inventory of Depressive Symptomatology. 
In a study published in 2011, using the Montgomery-Åsberg Depression Rating Scale and the Sheehan Disability Scale, edivoxetine showed superiority over placebo, with higher response and remission rates. 
In December 2013, Eli Lilly announced that the clinical development of edivoxetine will be stopped due to lack of efficacy compared to SSRI alone in three separate clinical trials .
Side effects significantly associated with edivoxetine are headache, nausea, constipation, dry mouth and insomnia. 
- Jun Yan (March 2012). "Pipeline for new antidepressants flowing slowly". Psychiatric News (American Psychiatric Association) 47 (5): 1b-29. Retrieved 2012-04-27.
- "Statement on a nonproprietary name adopted by the USAN council - Edivoxetine" (Press release). American Medical Association. 2012. Retrieved 2012-04-12.
- Chancellor D (November 2011). "The depression market". Nature Reviews. Drug Discovery 10 (11): 809–10. doi:10.1038/nrd3585. PMID 22037032.
- Dubé S, Dellva MA, Jones M, Kielbasa W, Padich R, Saha A, Rao P (April 2010). "A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression". Journal of Psychiatric Research 44 (6): 356–363. doi:10.1016/j.jpsychires.2009.09.013. PMID 19909980.
- Pangallo P, Dellva MA, D'Souza DN, Essink B, Russell J, Goldberger C (June 2011). "A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder". Journal of Psychiatric Research 45 (6): 748–755. doi:10.1016/j.jpsychires.2011.03.014. PMID 21511276.